Scotiabank Reduces Earnings Estimates for SNC-Lavalin Group

SNC-Lavalin Group Inc. (TSE:ATR – Free Report) – Equities researchers at Scotiabank lowered their FY2027 earnings per share (EPS) estimates for shares of SNC-Lavalin Group in a report issued on Wednesday, July 15th. Scotiabank analyst J. Goldman now expects that the company will post earnings per share of $4.32 for the year, down from their previous forecast of $4.39.

SNC-Lavalin Group Stock Performance

About SNC-Lavalin Group

(Get Free Report)

AptarGroup, Inc provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions.

Featured Stories

• Five stocks we like better than SNC-Lavalin Group
• Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
• Has Broadcom Become Too Expensive for Its AI Story?
• Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Revving Up Returns: Big Banks Race Through the Rate Plateau